published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsSeet 2021, 2021 1.00 [0.02; 50.64] 1.00[0.02; 50.64]Seet 2021, 202110%1,236NAnot evaluable new illness compatible with Covid-19 detailed resultsSeet 2021, 2021 0.03 [0.02; 0.04] 0.03[0.02; 0.04]Seet 2021, 202110%1,236NAnot evaluable symptomatic Covid-19detailed resultsSeet (HCQ), 2021 0.91 [0.57; 1.47] 0.91[0.57; 1.47]Seet (HCQ), 202110%645NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsSeet (HCQ), 2021 0.41 [0.32; 0.53] 0.41[0.32; 0.53]Seet (HCQ), 202110%1,051NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-05-10 19:46 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290